GlassScriptPhysician profile
Joshua Harbert
NPI 1508281825
$3,439.99
in general payments reported to CMS, 2019-2025
32 companies · $864 in 2025
The $864 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $160 · 2021: $593 · 2022: $458 · 2023: $272 · 2024: $380 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $490.25 | 2019-2025 | Wegovy |
| Pfizer INC. | $438.10 | 2019-2025 | |
| Lilly USA, LLC | $416.90 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $354.80 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $314.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.22 | 2019-2025 | Jardiance |
| Abbvie INC. | $197.20 | 2021-2025 | |
| Glaxosmithkline, LLC. | $137.03 | 2020-2025 | Bexsero, Shingrix, Arexvy |
| Astellas Pharma US INC | $133.77 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $99.24 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $92.06 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.70 | 2021-2024 | Xifaxan |
| Dexcom, INC. | $58.59 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $55.37 | 2023-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $41.67 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.42 | 2019 | |
| Avanir Pharmaceuticals, INC. | $30.32 | 2019 | |
| Tg Therapeutics, INC. | $27.78 | 2025 | |
| Esperion Therapeutics, INC. | $26.78 | 2021-2025 | Nexletol |
| Abbott Laboratories | $25.00 | 2025 | Freestyle Libre 2 |
| Bausch Health US, LLC | $23.44 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.17 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.00 | 2021 | |
| Currax Pharmaceuticals LLC | $16.54 | 2024 | Contrave |
| Sanofi Pasteur INC. | $15.03 | 2022 | |
| Amgen INC. | $14.97 | 2024 | Krystexxa |
| Daiichi Sankyo INC. | $14.85 | 2019 | |
| Ascensia Diabetes Care US INC. | $14.40 | 2024 | |
| Inspire Medical Systems, INC. | $14.26 | 2025 | Inspire |
| Horizon Therapeutics Plc | $11.65 | 2021 | |
| Mayne Pharma Commercial LLC | $10.40 | 2025 | |
| Phathom Pharmaceuticals, INC. | $7.42 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Harbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.